TLR4/MD2 specific peptides stalled in vivo LPS-induced immune exacerbation

Biomaterials

Volumn 126, Issue , 2017, Pages 49-60

  Park, Seolhee ^a   Shin, Hyeon Jun ^a   Shah, Masaud ^a   Cho, Hey Young ^a   Anwar, Muhammad Ayaz ^a   Achek, Asma ^a   Kwon, Hyuk Kwon ^a   Lee, Byugsung ^a   Yoo, Tae Hyeon ^a   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

Author keywords

Biopanning; In silico; Peptide drug; Phage display; Proinflammatory cytokine; Toll like receptor

Indexed keywords

ENZYME ACTIVITY; INTERFERONS;

BIOPANNING; IN-SILICO; PEPTIDE DRUGS; PHAGE DISPLAY; PROINFLAMMATORY CYTOKINES; TOLL-LIKE RECEPTORS;

PEPTIDES;

ACTIVATING TRANSCRIPTION FACTOR 3; ANTIGEN PEPTIDE TRANSPORTER 2; HISTONE DEACETYLASE 1; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE DERIVATIVE; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; LIGAND; PEPTIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE DISPLAY; PRIORITY JOURNAL; RAW 264.7 CELL LINE; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL SURFACE DISPLAY; COMPUTER SIMULATION; DRUG EFFECTS; IMMUNITY; METABOLISM; MONONUCLEAR CELL;

ANIMALS; CELL SURFACE DISPLAY TECHNIQUES; COMPUTER SIMULATION; HUMANS; IMMUNITY; LEUKOCYTES, MONONUCLEAR; LIGANDS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PEPTIDES; RAW 264.7 CELLS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85013957924     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.02.023     Document Type: Article

References (71)

1. [1] Lee, C.C., Avalos, A.M., Ploegh, H.L., Accessory molecules for Toll-like receptors and their function. Nat. Rev. Immunol. 12 (2012), 168–179.
2. [2] Takeda, K., Kaisho, T., Akira, S., Toll-like receptors. Annu. Rev. Immunol. 21 (2003), 335–376.
3. [3] O'Neill, L.A., Golenbock, D., Bowie, A.G., The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 13 (2013), 453–460.
4. [4] Akira, S., Takeda, K., Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004), 499–511.
5. [5] Takeda, K., Akira, S., Toll-like receptors in innate immunity. Int. Immunol. 17 (2005), 1–14.
6. [6] West, A.P., Brodsky, I.E., Rahner, C., Woo, D.K., Erdjument-Bromage, H., Tempst, P., et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472 (2011), 476–480.
7. [7] Cole, C., Thomas, S., Filak, H., Henson, P.M., Lenz, L.L., Nitric oxide increases susceptibility of Toll-like receptor-activated macrophages to spreading Listeria monocytogenes. Immunity 36 (2012), 807–820.
8. [8] Jimenez-Dalmaroni, M.J., Gerswhin, M.E., Adamopoulos, I.E., The critical role of toll-like receptors–From microbial recognition to autoimmunity: a comprehensive review. Autoimmun. Rev. 15 (2016), 1–8.
9. [9] Hennessy, E.J., Parker, A.E., O'Neill, L.A., Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug Discov. 9 (2010), 293–307.
10. [10] O'Neill, L.A., Bryant, C.E., Doyle, S.L., Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61 (2009), 177–197.
11. [11] Marshak-Rothstein, A., Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6 (2006), 823–835.
12. [12] Cook, D.N., Pisetsky, D.S., Schwartz, D.A., Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 5 (2004), 975–979.
13. [13] Rakoff-Nahoum, S., Medzhitov, R., Toll-like receptors and cancer. Nat. Rev. Cancer 9 (2009), 57–63.
14. [14] Shah, M., Anwar, M.A., Kim, J.H., Choi, S., Advances in antiviral therapies targeting toll-like receptors. Expert Opin. Investig. Drugs 25 (2016), 437–453.
15. [15] Patra, M.C., Choi, S., Recent progress in the development of Toll-like receptor (TLR) antagonists. Expert Opin. Ther. Pat. 26 (2016), 719–730.
16. [16] Peri, F., Piazza, M., Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol. Adv. 30 (2012), 251–260.
17. [17] Wang, X., Smith, C., Yin, H., Targeting Toll-like receptors with small molecule agents. Chem. Soc. Rev. 42 (2013), 4859–4866.
18. [18] Park, B.S., Song, D.H., Kim, H.M., Choi, B.S., Lee, H., Lee, J.O., The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458 (2009), 1191–1195.
19. [19] Kim, H.M., Park, B.S., Kim, J.I., Kim, S.E., Lee, J., Oh, S.C., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130 (2007), 906–917.
20. [20] Jarvis, B.W., Lichenstein, H., Qureshi, N., Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS. Infect. Immun. 65 (1997), 3011–3016.
21. [21] Peri, F., Calabrese, V., Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update. J. Med. Chem. 57 (2014), 3612–3622.
22. [22] Wang, Y., Su, L., Morin, M.D., Jones, B.T., Whitby, L.R., Surakattula, M.M., et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E884–E893.
23. [23] Hussey, S.E., Liang, H., Costford, S.R., Klip, A., DeFronzo, R.A., Sanchez-Avila, A., et al. TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells. Biosci. Rep. 33 (2012), 37–47.
24. [24] Matsunaga, N., Tsuchimori, N., Matsumoto, T., Ii, M., TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol. Pharmacol. 79 (2011), 34–41.
25. [25] Shanmugam, A., Rajoria, S., George, A.L., Mittelman, A., Suriano, R., Tiwari, R.K., Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PLoS One, 7, 2012, e30839.
26. [26] Slivka, P.F., Shridhar, M., Lee, G.I., Sammond, D.W., Hutchinson, M.R., Martinko, A.J., et al. A peptide antagonist of the TLR4-MD2 interaction. Chembiochem 10 (2009), 645–649.
27. [27] Yang, Q.W., Mou, L., Lv, F.L., Zhu, P.F., Wang, Z.G., Jiang, J.X., et al. Novel TLR4-antagonizing peptides inhibit LPS-induced release of inflammatory mediators by monocytes. Biochem. Biophys. Res. Commun. 329 (2005), 846–854.
28. [28] Sidhu, S.S., Lowman, H.B., Cunningham, B.C., Wells, J.A., Phage display for selection of novel binding peptides. Methods Enzymol. 328 (2000), 333–363.
29. [29] Rahbarnia, L., Farajnia, S., Babaei, H., Majidi, J., Veisi, K., Ahmadzadeh, V., et al. Evolution of phage display technology: from discovery to application. J. Drug Target, 2016, 1–9.
30. [30] Omidfar, K., Daneshpour, M., Advances in phage display technology for drug discovery. Expert Opin. Drug Discov. 10 (2015), 651–669.
31. [31] Smith, G.P., Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (1985), 1315–1317.
32. [32] Alizadeh, A.A., Hamzeh-Mivehroud, M., Farajzadeh, M., Dastmalchi, S., Identification of novel peptides against TNF-alpha using phage display technique and in silico modeling of their modes of binding. Eur. J. Pharm. Sci. 96 (2016), 490–498.
33. [33] Yan, Z., Wu, Y., Du, J., Li, G., Wang, S., Cao, W., et al. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy. Oncotarget 7 (2016), 40437–40450.
34. [34] Kubas, G., Rees, W., Caguiat, J., Asch, D., Fagan, D., Cortes, P., Identification of peptide sequences that selectively bind to pentaerythritol trinitrate hemisuccinate -a surrogate of PETN, via phage display technology. Biopolymers, 2016, 10.1002/bip.22997.
35. [35] Hou, Y., Gu, X.X., Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates. J. Immunol. 170 (2003), 4373–4379.
36. [36] Piao, W., Vogel, S.N., Toshchakov, V.Y., Inhibition of TLR4 signaling by TRAM-derived decoy peptides in vitro and in vivo. J. Immunol. 190 (2013), 2263–2272.
37. [37] Otvos, L. Jr., Wade, J.D., Current challenges in peptide-based drug discovery. Front. Chem., 2, 2014, 62.
38. [38] Gentilucci, L., De Marco, R., Cerisoli, L., Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16 (2010), 3185–3203.
39. [39] Bhardwaj, G., Mulligan, V.K., Bahl, C.D., Gilmore, J.M., Harvey, P.J., Cheneval, O., et al. Accurate de novo design of hyperstable constrained peptides. Nature 538 (2016), 329–335.
40. [40] Patil, S., Vhora, I., Amrutiya, J., Lalani, R., Misra, A., Role of nanotechnology in delivery of protein and peptide drugs. Curr. Pharm. Des. 21 (2015), 4155–4173.
41. [41] Zuo, B., Yang, J., Wang, F., Wang, L., Yin, Y., Dan, J., et al. Influences of lamin A levels on induction of pluripotent stem cells. Biol. Open 1 (2012), 1118–1127.
42. [42] Tonikian, R., Zhang, Y., Boone, C., Sidhu, S.S., Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nat. Protoc. 2 (2007), 1368–1386.
43. [43] Winter, G., Griffiths, A.D., Hawkins, R.E., Hoogenboom, H.R., Making antibodies by phage display technology. Annu. Rev. Immunol. 12 (1994), 433–455.
44. [44] TA, H., BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series, 1999, 95–98.
45. [45] Zhang, Y., I-TASSER server for protein 3D structure prediction. BMC Bioinforma., 9, 2008, 40.
46. [46] Bowie, J.U., Luthy, R., Eisenberg, D., A method to identify protein sequences that fold into a known three-dimensional structure. Science 253 (1991), 164–170.
47. [47] Laskowski, R.A., Rullmannn, J.A., MacArthur, M.W., Kaptein, R., Thornton, J.M., AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8 (1996), 477–486.
48. [48] Anwar, M.A., Panneerselvam, S., Shah, M., Choi, S., Insights into the species-specific TLR4 signaling mechanism in response to Rhodobacter sphaeroides lipid A detection. Sci. Rep., 5, 2015, 7657.
49. [49] Gilchrist, M., Thorsson, V., Li, B., Rust, A.G., Korb, M., Roach, J.C., et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441 (2006), 173–178.
50. [50] Kim, E.Y., Shin, H.Y., Kim, J.Y., Kim, D.G., Choi, Y.M., Kwon, H.K., et al. ATF3 plays a key role in Kdo2-lipid A-induced TLR4-dependent gene expression via NF-kappaB activation. PLoS One, 5, 2010, e14181.
51. [51] Yuan, X., Zhou, Y., Wang, W., Li, J., Xie, G., Zhao, Y., et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis., 4, 2013, e794.
52. [52] Ohto, U., Fukase, K., Miyake, K., Satow, Y., Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316 (2007), 1632–1634.
53. [53] Muroi, M., Tanamoto, K., Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J. Biol. Chem. 281 (2006), 5484–5491.
54. [54] Paramo, T., Piggot, T.J., Bryant, C.E., Bond, P.J., The structural basis for endotoxin-induced allosteric regulation of the Toll-like receptor 4 (TLR4) innate immune receptor. J. Biol. Chem. 288 (2013), 36215–36225.
55. [55] Cario, E., Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm. Bowel Dis. 16 (2010), 1583–1597.
56. [56] Heneka, M.T., Kummer, M.P., Latz, E., Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14 (2014), 463–477.
57. [57] Wenink, M.H., Santegoets, K.C., Roelofs, M.F., Huijbens, R., Koenen, H.J., van Beek, R., et al. The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease. J. Immunol. 183 (2009), 4509–4520.
58. [58] Okun, E., Griffioen, K.J., Lathia, J.D., Tang, S.C., Mattson, M.P., Arumugam, T.V., Toll-like receptors in neurodegeneration. Brain Res. Rev. 59 (2009), 278–292.
59. [59] Imai, Y., Kuba, K., Neely, G.G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133 (2008), 235–249.
60. [60] Lotharius, J., Brundin, P., Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 (2002), 932–942.
61. [61] Uttara, B., Singh, A.V., Zamboni, P., Mahajan, R.T., Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7 (2009), 65–74.
62. [62] Ross, C.A., Aylward, E.H., Wild, E.J., Langbehn, D.R., Long, J.D., Warner, J.H., et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10 (2014), 204–216.
63. [63] Ii, M., Matsunaga, N., Hazeki, K., Nakamura, K., Takashima, K., Seya, T., et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69 (2006), 1288–1295.
64. [64] Lysakova-Devine, T., Keogh, B., Harrington, B., Nagpal, K., Halle, A., Golenbock, D.T., et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J. Immunol. 185 (2010), 4261–4271.
65. [65] Babazada, H., Yamashita, F., Hashida, M., Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4-NF-kappaB signaling. J. Control Release 194 (2014), 295–300.
66. [66] Couture, L.A., Piao, W., Ru, L.W., Vogel, S.N., Toshchakov, V.Y., Targeting Toll-like receptor (TLR) signaling by Toll/interleukin-1 receptor (TIR) domain-containing adapter protein/MyD88 adapter-like (TIRAP/Mal)-derived decoy peptides. J. Biol. Chem. 287 (2012), 24641–24648.
67. [67] Piao, W., Shirey, K.A., Ru, L.W., Lai, W., Szmacinski, H., Snyder, G.A., et al. A decoy peptide that disrupts TIRAP recruitment to TLRs is protective in a Murine model of Influenza. Cell Rep. 11 (2015), 1941–1952.
68. [68] Huber, W., Mueller, F., Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr. Pharm. Des. 12 (2006), 3999–4021.
69. [69] Wang, X., Loram, L.C., Ramos, K., de Jesus, A.J., Thomas, J., Cheng, K., et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 6325–6330.
70. [70] Nagai, Y., Akashi, S., Nagafuku, M., Ogata, M., Iwakura, Y., Akira, S., et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3 (2002), 667–672.
71. [71] Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189 (1999), 1777–1782.